162 related articles for article (PubMed ID: 32683606)
1. Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.
Secombe KR; Ball IA; Shirren J; Wignall AD; Keefe DM; Bowen JM
Breast Cancer; 2021 Jan; 28(1):99-109. PubMed ID: 32683606
[TBL] [Abstract][Full Text] [Related]
2. Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model.
Secombe KR; Ball IA; Shirren J; Wignall AD; Finnie J; Keefe D; Avogadri-Connors F; Olek E; Martin D; Moran S; Bowen JM
Cancer Chemother Pharmacol; 2019 Mar; 83(3):531-543. PubMed ID: 30535958
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats.
Secombe KR; Ball IA; Wignall AD; Bateman E; Keefe DM; Bowen JM
Neoplasia; 2022 Aug; 30():100806. PubMed ID: 35561424
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor.
Abbas R; Hug BA; Leister C; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jul; 70(1):191-9. PubMed ID: 22418773
[TBL] [Abstract][Full Text] [Related]
5. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
Blackwell KL; Zaman K; Qin S; Tkaczuk KHR; Campone M; Hunt D; Bryce R; Goldstein LJ;
Clin Breast Cancer; 2019 Apr; 19(2):97-104.e4. PubMed ID: 30655172
[TBL] [Abstract][Full Text] [Related]
6. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
[TBL] [Abstract][Full Text] [Related]
7. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
Oaknin A; Friedman CF; Roman LD; D'Souza A; Brana I; Bidard FC; Goldman J; Alvarez EA; Boni V; ElNaggar AC; Passalacqua R; Do KTM; Santin AD; Keyvanjah K; Xu F; Eli LD; Lalani AS; Bryce RP; Hyman DM; Meric-Bernstam F; Solit DB; Monk BJ
Gynecol Oncol; 2020 Oct; 159(1):150-156. PubMed ID: 32723675
[TBL] [Abstract][Full Text] [Related]
8. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.
Mortimer J; Di Palma J; Schmid K; Ye Y; Jahanzeb M
Breast Cancer Res; 2019 Feb; 21(1):32. PubMed ID: 30813966
[TBL] [Abstract][Full Text] [Related]
9. Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.
Lüftner D; Tesch H; Schmidt M; Hartkopf AD; Streicher S; Resch A; Genovese L; Rosé C; Valenti R; Harbeck N
Eur J Cancer; 2021 Jun; 150():268-277. PubMed ID: 33971386
[TBL] [Abstract][Full Text] [Related]
10. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.
Iwata H; Masuda N; Kim SB; Inoue K; Rai Y; Fujita T; Chiu J; Ohtani S; Takahashi M; Miyaki T; Lu YS; Xu B; Yap YS; Bustam A; Yao B; Zhang B; Bryce R; Chan A
Future Oncol; 2019 Jul; 15(21):2489-2501. PubMed ID: 31140297
[No Abstract] [Full Text] [Related]
11. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Freedman RA; Gelman RS; Wefel JS; Melisko ME; Hess KR; Connolly RM; Van Poznak CH; Niravath PA; Puhalla SL; Ibrahim N; Blackwell KL; Moy B; Herold C; Liu MC; Lowe A; Agar NY; Ryabin N; Farooq S; Lawler E; Rimawi MF; Krop IE; Wolff AC; Winer EP; Lin NU
J Clin Oncol; 2016 Mar; 34(9):945-52. PubMed ID: 26834058
[TBL] [Abstract][Full Text] [Related]
12. Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU.
Dhillon S
Clin Drug Investig; 2019 Feb; 39(2):221-229. PubMed ID: 30607817
[TBL] [Abstract][Full Text] [Related]
13. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
[TBL] [Abstract][Full Text] [Related]
15. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
Tiwari SR; Mishra P; Abraham J
Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
[TBL] [Abstract][Full Text] [Related]
16. The calcium-sensing receptor: A novel target for treatment and prophylaxis of neratinib-induced diarrhea.
Lysyy T; Lalani AS; Olek EA; Diala I; Geibel JP
Pharmacol Res Perspect; 2019 Oct; 7(5):e00521. PubMed ID: 31523434
[TBL] [Abstract][Full Text] [Related]
17. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
Barcenas CH; Hurvitz SA; Di Palma JA; Bose R; Chien AJ; Iannotti N; Marx G; Brufsky A; Litvak A; Ibrahim E; Alvarez RH; Ruiz-Borrego M; Chan N; Manalo Y; Kellum A; Trudeau M; Thirlwell M; Garcia Saenz J; Hunt D; Bryce R; McCulloch L; Rugo HS; Tripathy D; Chan A;
Ann Oncol; 2020 Sep; 31(9):1223-1230. PubMed ID: 32464281
[TBL] [Abstract][Full Text] [Related]
18. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
Burstein HJ; Sun Y; Dirix LY; Jiang Z; Paridaens R; Tan AR; Awada A; Ranade A; Jiao S; Schwartz G; Abbas R; Powell C; Turnbull K; Vermette J; Zacharchuk C; Badwe R
J Clin Oncol; 2010 Mar; 28(8):1301-7. PubMed ID: 20142587
[TBL] [Abstract][Full Text] [Related]
19. Crofelemer for the Management of Neratinib-Associated Diarrhea in Patients With HER2+ Early-Stage Breast Cancer.
Jacob S; Johnson M; Roque B; Quintal L; Rugo HS; Melisko M; Chien AJ
Clin Breast Cancer; 2023 Oct; 23(7):721-728. PubMed ID: 37474374
[TBL] [Abstract][Full Text] [Related]
20. Risk of gastrointestinal complications in breast cancer patients treated with neratinib: a meta-analysis.
Jiang N; Song XW; Lin JJ; Wang ZY; Zhang BN; Li A; Yan RY; Yan HF; Fu XY; Zhou JL; Li CL; Cui Y
Expert Opin Drug Saf; 2017 Oct; 16(10):1111-1119. PubMed ID: 28766379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]